|
Jul 17
|
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
|
|
Jun 30
|
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
|
|
May 14
|
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
|
|
May 13
|
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
|
|
Mar 11
|
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
|